EXACT Therapeutics AS

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

ESG Focus Areas

Innovation
Patient Safety and Wellbeing
Responsible Supply Chain
Ethical R&D
Privacy and Data Management
Diversity, Equality and Inclusion
Business Ethics and Transparency
Stakeholder Relationship Management
Board Governance

Social Achievements

Appointed Caspar Foghsgaard as SVP Commercial & Business Development
Maintained low sickness absence (1.0%) and zero work-related accidents.

Governance Achievements

Established ethical guidelines presented in corporate governance policy and personnel handbook.
Ongoing work to establish a robust GDPR compliance policy.

Climate Goals & Targets

Medium-term Goals:

Initiate Phase 2 clinical trial (ENACT) in pancreatic cancer in the second half of 2024, with interim results expected in 2025.

Short-term Goals:

Complete the dose expansion part of the ACTIVATE trial in 2024.

Environmental Challenges

Challenges in the capital market
Insufficient cash position to fund operations and obligations for the next 12 months, particularly Phase 2 trials.

Mitigation Strategies

Raised NOK 25 million through a private placement (no share discounts).
Engaging in discussions with industry expert groups and potential investors.
Assessing opportunities to reduce costs.

Supply Chain Management

Responsible Procurement

Collaboration with GE Healthcare to reduce greenhouse gas usage in microbubble manufacturing.

Climate-Related Risks & Opportunities

UN Sustainable Development Goals

SDG 3 (Good Health and Well-being)
SDG 8 (Decent Work and Economic Growth)
SDG 9 (Industry, Innovation and Infrastructure)
SDG 12 (Responsible Consumption and Production)
SDG 17 (Partnerships for the Goals)

Developing innovative solutions for enhancing therapeutic efficacy of medicines; responsible production; partnerships with others to promote innovation and economic growth; decent work conditions.

Sustainable Products & Innovation

Acoustic Cluster Therapy (ACT®)